Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aslan Pharmaceuticals Ltd ADR (ASLN)

Aslan Pharmaceuticals Ltd ADR (ASLN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,698
  • Shares Outstanding, K 69,745
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,320 K
  • 60-Month Beta 1.90
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.24
Trade ASLN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.54
  • Most Recent Earnings -0.16 on 10/28/22
  • Next Earnings Date 03/24/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -888.63%)
  • Historical Volatility 125.81%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 985.60% on 11/25/22
  • IV Low 0.00% on 02/02/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 161
  • Open Int (30-Day) 198

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.19
  • Number of Estimates 2
  • High Estimate -0.18
  • Low Estimate -0.20
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4480 +62.25%
on 01/04/23
0.8000 -9.14%
on 01/24/23
+0.2917 (+67.03%)
since 01/03/23
3-Month
0.3500 +107.69%
on 12/30/22
0.8000 -9.14%
on 01/24/23
+0.3279 (+82.18%)
since 11/03/22
52-Week
0.3405 +113.48%
on 11/02/22
1.1137 -34.73%
on 02/11/22
-0.2531 (-25.83%)
since 02/03/22

Most Recent Stories

More News
DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study

The FDA lifts the partial clinical hold on DBV Technologies' (DVBT) phase III VITESSE study of a modified Viaskin Peanut patch in peanut-allergic children aged four to seven years. Stock rises.

ADAP : 1.6600 (-4.05%)
DBVT : 1.4000 (-3.45%)
ASLN : 0.7269 (-2.06%)
IMCR : 64.29 (+1.21%)
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly

ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.

LLY : 339.08 (+2.53%)
PRQR : 3.15 (+10.53%)
ASLN : 0.7269 (-2.06%)
IMCR : 64.29 (+1.21%)
ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study

ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter's elranatamab in multiple myeloma. Stock up in after-hours trading.

PFE : 44.06 (-0.63%)
ASLN : 0.7269 (-2.06%)
ORIC : 5.72 (-5.14%)
IMCR : 64.29 (+1.21%)
Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC

The FDA bestows a Breakthrough Therapy designation to Mirati's (MRTX) Krazati (adagrasib) for treating patients with advanced, KRAS-mutated colorectal cancer.

MRK : 102.94 (-0.50%)
AMGN : 245.17 (-0.55%)
MRTX : 52.57 (-3.11%)
ASLN : 0.7269 (-2.06%)
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis

The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis.

REGN : 783.13 (+4.25%)
SNY : 46.02 (-2.58%)
ASLN : 0.7269 (-2.06%)
IPHA : 3.48 (+2.19%)
Apellis (APLS) Files MAA for Pegcetacoplan in GA in Europe

Apellis (APLS) submits a marketing authorization application for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration to the European Medicines Agency.

AZN : 63.44 (+0.46%)
APLS : 54.77 (-3.45%)
ASLN : 0.7269 (-2.06%)
IMCR : 64.29 (+1.21%)
Ultragenyx's (RARE) Portfolio of Marketed Drugs Aids Growth

Ultragenyx's (RARE) marketed drugs, which are approved for various indications, are driving the top line. The company also has a strong pipeline. However, pipeline setbacks remain concerning.

REGN : 783.13 (+4.25%)
RARE : 45.73 (-3.40%)
ASLN : 0.7269 (-2.06%)
IMCR : 64.29 (+1.21%)
AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie

AbCellera (ABCL) inks a strategic collaboration with AbbVie to develop new antibody therapies across multiple indications. ABCL shares rise.

ABBV : 145.20 (+0.25%)
ASLN : 0.7269 (-2.06%)
ABCL : 11.18 (+1.54%)
RLYB : 6.45 (-4.87%)
Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474

Kymera (KYMR) posts positive data from a phase I study on KT-474 for treating patients with hidradenitis suppurativa and atopic dermatitis. Sanofi to advance KT-474 in phase II study.

SNY : 46.02 (-2.58%)
AGLE : 0.5040 (+2.86%)
ASLN : 0.7269 (-2.06%)
KYMR : 37.15 (-4.13%)
Sanofi's (SNY) Dupixent Gets Europe Nod for Prurigo Nodularis

The EC approves Sanofi (SNY) and its partner Regeneron's Dupixent for the treatment of adult patients with prurigo nodularis.

REGN : 783.13 (+4.25%)
SNY : 46.02 (-2.58%)
AGLE : 0.5040 (+2.86%)
ASLN : 0.7269 (-2.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company's product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003...

See More

Key Turning Points

3rd Resistance Point 0.7749
2nd Resistance Point 0.7586
1st Resistance Point 0.7427
Last Price 0.7269
1st Support Level 0.7105
2nd Support Level 0.6942
3rd Support Level 0.6783

See More

52-Week High 1.1137
Fibonacci 61.8% 0.8183
Fibonacci 50% 0.7271
Last Price 0.7269
Fibonacci 38.2% 0.6359
52-Week Low 0.3405

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar